Institutes
Refine
Year of publication
- 2020 (245) (remove)
Document Type
- Article (196)
- Preprint (39)
- Doctoral Thesis (10)
Language
- English (245) (remove)
Has Fulltext
- yes (245)
Is part of the Bibliography
- no (245)
Keywords
- COVID-19 (9)
- SARS-CoV-2 (5)
- bladder cancer (4)
- Aortic stenosis (3)
- Hypoxia (3)
- Inflammation (3)
- Macrophages (3)
- Mortality (3)
- Peri-implantitis (3)
- Postural control (3)
- Quality of life (3)
- Stroke (3)
- TAVI (3)
- Treatment (3)
- inflammation (3)
- macrophage (3)
- miRNA (3)
- Ataxia telangiectasia (2)
- Bibliometrics (2)
- Clinical decision support systems (2)
- Computer-assisted diagnosis (2)
- EEG (2)
- Endoscopy (2)
- Epidemiology (2)
- Epilepsy (2)
- Genetics (2)
- Glioma (2)
- Healthy adults (2)
- Long-term potentiation (2)
- Outcome (2)
- Pneumonia (2)
- Rare diseases (2)
- Seizure (2)
- Wearable cardioverter-defibrillator (2)
- Women (2)
- bibliometrics (2)
- cancer (2)
- cerebral hemorrhage (2)
- cerebral venous thrombosis (2)
- coagulopathy (2)
- drug resistance (2)
- mTOR (2)
- obesity (2)
- patient blood management (2)
- polytrauma (2)
- post-translational modifications (2)
- psoriasis (2)
- public health (2)
- quality of life (2)
- sphingosine 1-phosphate (2)
- spinal dural leaks (2)
- stroke (2)
- sulforaphane (2)
- superficial siderosis (2)
- thymus (2)
- 3D printing (1)
- 3D rapid prototyping (1)
- 4-fluoroamphetamine (1)
- AAA+ disaggregase (1)
- ADAMTS13 (1)
- ADGRE1 (1)
- ADHD (1)
- AML (1)
- ARDS (1)
- ASPECTS (1)
- Abductor pollicis longus (1)
- Ablation (1)
- Abrasion (1)
- Abusive head trauma (AHT) (1)
- Accumulated degree days (1)
- Acute appendicitis (1)
- Acute elbow dislocation (1)
- Acute lymphoblastic leukemia (1)
- Acute-on-chronic subdural hematoma (1)
- Adherence (1)
- Administrative claims data (1)
- Adverse drug reaction (1)
- Age determination (1)
- Albumin ratio (1)
- Allogeneic (1)
- Amisulpride (1)
- Amitriptyline (1)
- Anal cancer (1)
- Anandamide (1)
- Anatomy (1)
- Anderson–Fabry (1)
- Angiogenesis (1)
- Animal model (1)
- Anti-inflammatory (1)
- Anti-rheumatic agents (1)
- Anticholinergic (1)
- Anticoagulant (1)
- Anticoagulation (1)
- Aortic input function (1)
- Appendectomy (1)
- Arrhythmia syndromes (1)
- Arthroplasty (1)
- Artificial intelligence (1)
- Ataxia score (1)
- Atm (1)
- Atrial fibrillation (1)
- Attention deficit (1)
- Autism spectrum disorder (1)
- Autoimmune vasculopathy (1)
- Autologous biomaterial (1)
- Axiography (1)
- BEZ235 (1)
- BMC (1)
- BMI (1)
- Bacterial abundance (1)
- Balloon-expandable TAVI (1)
- Benign enlargement of the subarachnoid spaces (BESS) (1)
- Bioenergetics (1)
- Biopsy (1)
- Bladder cancer (1)
- Bleeding (1)
- Blocked occlusion (1)
- Body modification (1)
- Bone defect (1)
- Bone regeneration (1)
- Bone remodelling (1)
- Bone substitute (1)
- Bone tissue engineering (1)
- Brain asymmetry (1)
- Brain injuries (1)
- Brain tumor surgery (1)
- Breast cancer survivers (1)
- Burden of illness (1)
- CAD/CAM (1)
- CCL2 (1)
- CD34 + cells (1)
- CD44 (1)
- CDI (1)
- CEBPD (1)
- COMP (1)
- COVID 19 pandemic (1)
- Calpain (1)
- Cancer (1)
- Capnography (1)
- Cardiac arrest (1)
- Cardiology (1)
- Cardiovascular magnetic resonance (1)
- Caspase-8 (1)
- Cell death and immune response (1)
- Cerebral hypoperfusion (1)
- Cerebrospinal fluid (1)
- Cerebrovascular disorders (1)
- Cezanne (1)
- Chemoradiotherapy (1)
- Child (1)
- Child abuse (1)
- Chronic inflammation (1)
- Classification (1)
- Clavien–Dindo classification (1)
- Climate inequity (1)
- Clinical genetics (1)
- Clinical trial (1)
- Coagulation (1)
- Cognition (1)
- Cold hardiness (1)
- Cold tolerance (1)
- Collagen-based biomaterial (1)
- Colonic neoplasms (1)
- Complications (1)
- Compression stocking (1)
- Computational biophysics (1)
- Confinement (1)
- Congenital diaphragmatic hernia (1)
- Connectivity (1)
- Conservative treatment (1)
- Constitution (1)
- Control (1)
- Cooperation (1)
- Copy number (1)
- Coronary artery disease (1)
- Cortical degeneration (1)
- Cortical thickness (1)
- Craniomaxillofacial injuries (1)
- Critical care (1)
- Critical size (1)
- Cryoelectron microscopy (1)
- Cystic fibrosis (1)
- Cytokines (1)
- DBS (1)
- DNA methylation (1)
- DST (1)
- Data science (1)
- Decontamination (1)
- Deep vein thrombosis (1)
- Defibrillation (1)
- Density equalizing mapping (1)
- Density-equalizing mapping (1)
- Dental air (1)
- Dental casts (1)
- Dental implant (1)
- Dental implants (1)
- Dental practice (1)
- Dental students (1)
- Depression (1)
- Diagnosis (1)
- Diagnostic algorithm (1)
- Diagnostic error (1)
- Differential diagnosis (1)
- Disaster victim identification (1)
- Disintegration (1)
- Distribution limits (1)
- Dopamine (1)
- Double-blind placebo-controlled trial (1)
- Drug susceptibility testing (1)
- Dural onlays (1)
- Dysphagia (1)
- EGFR (1)
- EGFRvIII mutation (1)
- EMR1 (1)
- EMT (1)
- Edoxaban (1)
- Education (1)
- Ejection fraction (1)
- Elderly (1)
- Electrical stimulation (1)
- Emergency treatment (1)
- Endocrinology (1)
- Endometrial carcinoma (1)
- Endothelial cells (1)
- Endothelial protein C receptor (1)
- Energy metabolism (1)
- Enterobacteriaceae (1)
- Epidural abscess (1)
- Evaluation (1)
- Evidence-based dentistry (1)
- Evidence-based medicine (1)
- Exercise challenge (1)
- Exercise-induced asthma (1)
- Exhaled nitric oxide (1)
- F4/80 (1)
- FBK-R23 (1)
- FEV1 (1)
- FHIR (1)
- FIH1 (1)
- FTMT (1)
- Fasting (1)
- Feedback (1)
- Female subjects (1)
- Ferritinophagy (1)
- Ferroptosis (1)
- Finevo (1)
- Fluid therapy (1)
- Forced expiratory volume in 1 s (1)
- Forensic entomology (1)
- Forensic examination (1)
- Fracture (1)
- Fracture type (1)
- Functional characterization (1)
- G-CSF (1)
- GLA deficiency (1)
- Gait analysis (1)
- Gastroschisis (1)
- Gene regulation (1)
- General practice (1)
- Genetic heart disease (1)
- Genetic syndromes (1)
- Geographical disparities (1)
- Global warming (1)
- Graph theory (1)
- Greenhouse effect (1)
- Guided bone regeneration (GBR) (1)
- Guided tissue regeneration (GTR) (1)
- HADS (1)
- HDAC and BET inhibitor (1)
- HDAC4 (1)
- HIV (1)
- HOSO (1)
- Haematocrit (1)
- Health care (1)
- Healthcare costs (1)
- Healthcare resource utilization (1)
- Heart failure (1)
- Heat shock protein 27 (1)
- Hemispheric specialization (1)
- Hemodynamics (1)
- Heterogeneity (1)
- High oblique sagittal osteotomy (1)
- Hippocampal excitability (1)
- Hippocampus (1)
- Histological analysis (1)
- HoLEP (1)
- Human behaviour (1)
- Hyperactivity (1)
- Hyperscanning (1)
- Hypoxia-inducible factor-1α (HIF-1α) (1)
- ICAM-1 (1)
- ICD (1)
- IDH mutation (1)
- IL-1β (1)
- ISR (1)
- Identification (1)
- Identifikation (1)
- Identifizierung von Katastrophenopfern (1)
- Immunohistochemistry (1)
- Immunology (1)
- Immunomodulatory agents (1)
- Implant osseointegration (1)
- Imrt (1)
- In vitro (1)
- In vivo (1)
- Inducible nitric oxide synthase (iNOS) (1)
- Induction chemotherapy (1)
- Infections (1)
- Inflammatory pattern (1)
- Injury Severity Score (ISS) (1)
- Innate immunity (1)
- Integrated Pulmonary Index (1)
- Integration (1)
- IntelliCage (1)
- Interoperability (1)
- Interposition (1)
- Interstitial pneumonia (1)
- Interview (1)
- Intravenous antibiotic therapy (1)
- Iron (1)
- Isocitrate dehydrogenase (1)
- JNK (1)
- Joint actions (1)
- Joint loading (1)
- K-homology RNA-binding domain (1)
- Kidney diseases (1)
- Körpermodifizierung (1)
- L-DOPA (1)
- Language delay (1)
- Lennox-Gastaut syndrome (1)
- Lockdown (1)
- Longchain polyunsaturated fatty acids (1)
- Low-dose radiation therapy (1)
- Lung cancer (1)
- Lung development (1)
- Lung function (1)
- Lung ultrasound (1)
- Lysophosphatidic acids (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- MRI (1)
- MS (1)
- Machine learning (1)
- Machine-learning (1)
- Macrophage polarization (1)
- Magnetic resonance imaging (1)
- Management (1)
- Mass disaster (1)
- Massenkatastrophe (1)
- Maxillofacial surgery (1)
- Mean erythrocyte volume (1)
- Medical research (1)
- Meta-analysis (1)
- Metabolic diseases (1)
- Michael acceptor (1)
- Microparticles (1)
- Mitochondrial dysfunction (1)
- Mobilization (1)
- Molecular autopsy (1)
- Molecular neuroscience (1)
- Monetary incentive delay (1)
- Mongolian spot (1)
- Monitoring (1)
- Monocytes (1)
- Morbidity (1)
- Morphologie (1)
- Morphology (1)
- Multidrug-resistance (1)
- Multimedication (1)
- Multimorbidity (1)
- Multiparametric MRI (1)
- Multiplate (1)
- Multiple-indication review (1)
- Myocardial infarction (MI) (1)
- Myocardial injury (1)
- Myocardial perfusion (1)
- NAFLD (1)
- NCOA4 (1)
- NCoR1 (1)
- NF-κB pathway (1)
- NIRS (1)
- NLRP3 inflammasomes (1)
- NTM (1)
- Negative appendectomy rate (1)
- Nek1 (1)
- Neonatal surgery outcome (1)
- Neurodegeneration (1)
- Neuron (1)
- Neurosurgery (1)
- Neurotransmitter (1)
- Nevus of Ito (1)
- Nevus of Ota (1)
- Next-generation sequencing (1)
- Non-abusive head trauma (NAHT) (1)
- Non-apoptotic functions (1)
- Non-tuberculous mycobacteria (1)
- Non-vitamin K antagonist oral anticoagulants (1)
- Normative modeling (1)
- Number of platelets (1)
- OSA (1)
- OTU domain-containing protein 7B (OTUD7B) (1)
- Omphalocele (1)
- Oncology (1)
- Oral anticoagulation (1)
- Orthognathic surgery (1)
- Osteoarthritis (1)
- Outcomes (1)
- Ovarian cancer treatment (1)
- Overwintering (1)
- PI3K/mTor inhibition (1)
- PV loop (1)
- PWI (1)
- Paediatric trauma patients (1)
- Pain (1)
- Parasympathetic (1)
- Patient blood management (1)
- Patient outcome assessment (1)
- Patient safety (1)
- Patterns of care (1)
- Pelvic (1)
- Percutaneous endoscopic gastrostomy (1)
- Periodontitis grades B and C (1)
- Periprocedural anticoagulation (1)
- Perrault syndrome (1)
- Phalangeal fractures (1)
- Phase I clinical trial (1)
- Phenotypic plasticity (1)
- Physical activity (1)
- Platelet-rich fibrin (1)
- Polygenic risk score (1)
- Polypharmacy (1)
- Post mortem interval (1)
- Pressure distribution (1)
- Pressure measuring plate (1)
- Prevalence (1)
- Prevention (1)
- Primary health care (1)
- Procedural skills (1)
- Prostate cancer (1)
- Pseudoprogression (1)
- Psychology (1)
- Pteridine (1)
- Pulmonary edema (1)
- Pulmonary embolism (1)
- Pulmonary hypertension (1)
- Pulmonary hypoplasia (1)
- Qualitative research (1)
- Quantitative (q)T2 mapping (1)
- Quantitative magnetic resonance imaging (1)
- Quantra (1)
- Questionnaire (1)
- Quinolones (1)
- RIPK1 (1)
- RNA chaperone (1)
- Radiomics (1)
- Ramadan (1)
- Refractory ALL (1)
- Refractory AML (1)
- RegJoint™ (1)
- Regeneration (1)
- Registries (1)
- Regret (1)
- Reliability (1)
- Rescue medication (1)
- Research investment (1)
- Respiratory distress syndrome (1)
- Retinal diseases (1)
- Retinoic acid (1)
- Return to work (1)
- Reward (1)
- Rheumatoid arthritis (1)
- Risk-stratification (1)
- S1P receptors (1)
- SCA2 (1)
- SCN5A (1)
- SEAP (1)
- SIDS (1)
- SLUG (1)
- SNORD95 (1)
- Safety (1)
- Saudi Arabia (1)
- Second donation (1)
- Self-expandable TAVI (1)
- Serious injured children (1)
- Serum biomarker (1)
- Sex (1)
- Sharp injuries (1)
- Shoulder luxation (1)
- Side effects (1)
- Signal intensity (1)
- Signs and symptoms (1)
- Social brain (1)
- Social differences (1)
- Socio-economic analysis (1)
- Socioeconomic analysis (1)
- Socioeconomic indices (1)
- Spine fractures (1)
- Spinocerebellar ataxia type 2 (1)
- Stage at presentation (1)
- Standard dataset (1)
- Standard reference values (1)
- Standard value (1)
- Status epilepticus (1)
- Stem cell (1)
- Sterols (1)
- Striatum (1)
- Stroke genetics (1)
- Sub-zero exposure (1)
- Sudden death (1)
- Sudden infant death syndrome (1)
- Surgery (1)
- Surgical therapy (1)
- Survey (1)
- Suspension (1)
- Swallowing (1)
- Sympathetic (1)
- Synaptic transmission (1)
- T cell receptor (1)
- T cells (1)
- T-cell receptor (1)
- T2 (1)
- TAMs (1)
- TGF-β (1)
- TGR(mREN2)27 (1)
- TRIMs (1)
- Targeted sequencing (1)
- Test assay (1)
- Therapies (1)
- Thrombotic thrombocytopenic purpura (1)
- Thumb carpometacarpal joint osteoarthritis (1)
- Tissue engineering (1)
- Tocilizumab (1)
- Total hip arthroplasty (1)
- Touchscreen (1)
- Transcription regulation (1)
- Transcriptional regulatory elements (1)
- Transfusion (1)
- Transfusion practice (1)
- Transgenic mice (1)
- Translation proteomics (1)
- TraumaRegister DGU® (TR-DGU) (1)
- Treatment effectiveness (1)
- Treatment rates (1)
- Treg cell (1)
- Tumor microenvironment (1)
- Type 2 diabetes (1)
- UBA domain (1)
- Ubiquitin ligase (1)
- Uncertainty (1)
- Undergraduate education (1)
- Upper body posture (1)
- VIM (1)
- Validation (1)
- Vascular endothelial growth factor (VEGF) (1)
- Venous thromboembolism (1)
- Ventricular arrhythmia (1)
- Ventricular arrhythmias (1)
- Videorasterstereography (1)
- Volume therapy (1)
- Volunteer donor (1)
- Watertight Dural closure (1)
- Western diet (1)
- Winter survival (1)
- Wound healing (1)
- Wounds (1)
- [18F]FET PET (1)
- activated clotting time measurement (1)
- adaptation (1)
- adhesion (1)
- adiabatic saturation (1)
- adipose-derived mesenchymal stem/stromal cells (1)
- adult (1)
- aging (1)
- alcoholic hepatitis (1)
- algorithm (1)
- allogeneic donor (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alpha power (1)
- alpha-galactosidase A deficiency (1)
- alternative matrices (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anaemia walk-in clinic (1)
- angiokeratoma diffuse (1)
- anti-inflammatory drug (1)
- aortic stenosis (1)
- apoptosis (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- aspiration (1)
- auditory fMRI (1)
- bacteria (1)
- bio imaging (1)
- bioactive lipids (1)
- bioavailability (1)
- bioluminescence (1)
- bipolar disorder (1)
- blinatumomab (1)
- blood pressure (1)
- blood transfusion (1)
- brain (1)
- brain shift (1)
- brain tumor (1)
- breast cancer (1)
- bypass (1)
- caesarean scar (1)
- caesarean section (1)
- cancer information (1)
- cancer specific survival (1)
- cardiothoracic surgery (1)
- cell death (1)
- ceramides (1)
- cerumen (1)
- cervical cancer (1)
- chemoprotection (1)
- chemoresistance (1)
- chemotaxis (1)
- chemotherapy (1)
- clinical immunology (1)
- coagulation (1)
- cognitive aging (1)
- colorectal cancer (1)
- colorectal cancer (CRC) (1)
- contamination (1)
- cortex (1)
- covalent drugs (1)
- curcumin (1)
- cyclin Y (1)
- cyclooxygenase 2 (1)
- cytokine storm (1)
- cytotoxic lymphocytes (1)
- cytotoxicity (1)
- data science (1)
- debris (1)
- deferred treatment (1)
- delayed treatment (1)
- delirium (1)
- demineralized bone matrix (1)
- dentoalveolar surgery (1)
- deubiquitinase (DUB) (1)
- deubiquitylation (deubiquitination) (1)
- donor safety (1)
- drug abstinence (1)
- dysphagia (1)
- early detection (1)
- electronic adherence measurement (1)
- electrophilic fatty acids (1)
- epidemics (1)
- epidemiology (1)
- epilepsy (1)
- episodic memory (1)
- epithelial-to-mesenchymal transition (EMT) (1)
- essential tremor (1)
- euthymic (1)
- everolimus (1)
- evolution (1)
- exercise (1)
- experimental pain models (1)
- fMRI (1)
- flow cytometry (1)
- focal cortical dysplasia (1)
- fractionation (1)
- fragile-X-associated tremor-ataxia syndrome (1)
- fronto-temporal lobar dementia (1)
- fronto-temporal-lobar-dementia (1)
- functional connectivity (1)
- gene regulation (1)
- geriatric patients (1)
- glioblastoma (1)
- glioblastoma cells (1)
- glioma (1)
- graph theory (1)
- growth (1)
- hemorrhage (1)
- hepatic stellate cells (1)
- hepatitis C virus (HCV) (1)
- hepatocellular cancer (1)
- hereditary dystopic lipidosis (1)
- high-throughput screening (1)
- hippocampus (1)
- histological outcomes (1)
- human genomics (1)
- hybrid abutment (1)
- hydroxylation (1)
- hypoxia (1)
- imaging (1)
- immune checkpoint (1)
- immune defense (1)
- immune response (1)
- immunity (1)
- immuno-oncotherapy (1)
- immunosuppression (1)
- immunotherapy (1)
- in vitro models (1)
- infection (1)
- inferior frontal gyrus (1)
- innate immunity (1)
- inositol signaling (1)
- integrated stress response (1)
- integrin (1)
- integrins (1)
- inter-individual variability (1)
- interferon type III (1)
- investigational (1)
- inflammation (1)
- iron deficiency (1)
- joint contact forces (1)
- knee adduction moment (1)
- lichen extracts (1)
- lipoxin A4 (1)
- liquid chromatography–mass spectrometry (1)
- liver fibrosis (1)
- long-term potentiation (1)
- long-term success (1)
- lymphocytes (1)
- machine learning (1)
- medication adherence rate (1)
- mental distress (1)
- mesenchymal stromal cells (1)
- mesenchymal stromal/stem cells (1)
- metabolism (1)
- miR-142-3p (1)
- miR-181 (1)
- miR-6862-5p (1)
- microRNA (1)
- mid-IR spectroscopy (1)
- migration (1)
- minimal residual disease (1)
- mitochondria (1)
- mitochondrial antiviral signaling protein (MAVS) (1)
- mitochondrial metabolism (1)
- mitochondrial morphology (1)
- mixed lineage kinase domain-like (1)
- molecular adaptation (1)
- molecular biology (1)
- molecular dynamics (1)
- monotype abutment (1)
- monsoon (1)
- mortality analysis (1)
- mortality risk (1)
- musculoskeletal inflammation (1)
- musculoskeletal modeling (1)
- neural oscillations (1)
- neurexin (1)
- next-generation sequencing (1)
- nitroalkylation (1)
- noninvasive blood glucose analysis (1)
- nuclear magnetic resonance (NMR) (1)
- nutrient endocytosis (1)
- oncogenic signaling (1)
- oral and maxillofacial surgery (1)
- orthopaedic patients (1)
- osteoarthritis (1)
- outside-in signaling (1)
- pain (1)
- patient’s decree (1)
- perceptual closure (1)
- pericytes (1)
- periodontal risk factors (1)
- photothermal detection (1)
- placenta (1)
- planimetric measurement (1)
- plasma (1)
- pneumocystis (1)
- point of care (1)
- poly(A)-tail (1)
- portal hypertension (1)
- post-caesarean uterus (1)
- post-exercise hypotension (1)
- posterior fossa tumor (1)
- postmonsoon (1)
- posttranslational modification (PTM) (1)
- precision weighting (1)
- predictive coding (1)
- prevalence (1)
- prognosis (1)
- prognostic marker (1)
- proliferation (1)
- prostate cancer (1)
- protease inhibitor (1)
- protein-protein interaction (1)
- proteostasis (1)
- psoriatic arthritis (1)
- qRT-PCR (1)
- quantum cascade laser (QCL) (1)
- radical prostatectomy (1)
- radiosensitization (1)
- rat femur critical size defect (1)
- regulatory T cell (1)
- regulatory T helper cells (1)
- relaxometry (1)
- renal cell carcinoma (1)
- renal transplantation (1)
- replicative fitness (1)
- resistance mutation (1)
- resolution of inflammation (1)
- reticulocyte haemoglobin (1)
- risk factor (1)
- risk factors (1)
- rotational thromboelastometry (1)
- scanner noise (1)
- schizophrenia (1)
- screening (1)
- selection (1)
- serine protease (NS3-4A) (1)
- serum (1)
- severely injured (1)
- signaling (1)
- simulation training (1)
- sonography (1)
- sparse imaging (1)
- spatial learning (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- sphingosine 1-phosphate receptor (1)
- sphingosine kinase (1)
- sphingosine-1-phosphate (1)
- spreading (1)
- starvation (1)
- steady-state condition (1)
- steatosis (1)
- stem cell transplantation (1)
- stem cells (1)
- stress (1)
- structure constraints (1)
- supportive periodontal therapy (1)
- survival (1)
- swallowing (1)
- synaesthesia (1)
- synaptic plasticity (1)
- tauopathies (1)
- tauopathy (1)
- thrombosis (1)
- tooth loss (1)
- total hip replacement (1)
- tracking (1)
- transcriptome (1)
- transferrin (1)
- translatome (1)
- transplantation (1)
- trauma registry (1)
- traumaticbraininjury(TBI) (1)
- tumor microenvironment (1)
- tyrosine kinase inhibitor (1)
- tyrosine kinase receptor signaling (1)
- ubiquitin (1)
- ubiquitin hydrolase (1)
- ultrasonic cleaning (1)
- unconventional T cell (1)
- uterine wall (1)
- variable silent delay (1)
- ventralis intermedius nucleus (1)
- vertical transmission (1)
- viruses (1)
- vitamin k antagonists (1)
- waiting time (1)
- walking (1)
- white matter hyperintensity (1)
- xenograft (1)
- fibrogenesis (1)
- fingolimod (1)
Institute
- Medizin (245)
- Biowissenschaften (3)
- Ernst Strüngmann Institut (3)
- Frankfurt Institute for Advanced Studies (FIAS) (3)
- MPI für Hirnforschung (3)
- Psychologie (2)
- Biochemie und Chemie (1)
- Biochemie, Chemie und Pharmazie (1)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (1)
- Informatik und Mathematik (1)
Aims: Systemic inflammatory response, identified by increased total leucocyte counts, was shown to be a strong predictor of mortality after transcatheter aortic valve implantation (TAVI). Yet the mechanisms of inflammation-associated poor outcome after TAVI are unclear. Therefore, the present study aimed at investigating individual inflammatory signatures and functional heterogeneity of circulating myeloid and T-lymphocyte subsets and their impact on 1 year survival in a single-centre cohort of patients with severe aortic stenosis undergoing TAVI. Methods and results: One hundred twenty-nine consecutive patients with severe symptomatic aortic stenosis admitted for transfemoral TAVI were included. Blood samples were obtained at baseline, immediately after, and 24 h and 3 days after TAVI, and these were analysed for inflammatory and cardiac biomarkers. Myeloid and T-lymphocyte subsets were measured using flow cytometry. The inflammatory parameters were first analysed as continuous variables; and in case of association with outcome and area under receiver operating characteristic (ROC) curve (AUC) ≥ 0.6, the values were dichotomized using optimal cut-off points. Several baseline inflammatory parameters, including high-sensitivity C-reactive protein (hsCRP; HR = 1.37, 95% CI: 1.15–1.63; P < 0.0001) and IL-6 (HR = 1.02, 95% CI: 1.01–1.03; P = 0.003), lower counts of Th2 (HR = 0.95, 95% CI: 0.91–0.99; P = 0.009), and increased percentages of Th17 cells (HR = 1.19, 95% CI: 1.02–1.38; P = 0.024) were associated with 12 month all-cause mortality. Among postprocedural parameters, only increased post-TAVI counts of non-classical monocytes immediately after TAVI were predictive of outcome (HR = 1.03, 95% CI: 1.01–1.05; P = 0.003). The occurrence of SIRS criteria within 48 h post-TAVI showed no significant association with 12 month mortality (HR = 0.57, 95% CI: 0.13–2.43, P = 0.45). In multivariate analysis of discrete or dichotomized clinical and inflammatory variables, the presence of diabetes mellitus (HR = 3.50; 95% CI: 1.42–8.62; P = 0.006), low left ventricular (LV) ejection fraction (HR = 3.16; 95% CI: 1.35–7.39; P = 0.008), increased baseline hsCRP (HR = 5.22; 95% CI: 2.09–13.01; P < 0.0001), and low baseline Th2 cell counts (HR = 8.83; 95% CI: 3.02–25.80) were significant predictors of death. The prognostic value of the linear prediction score calculated of these parameters was superior to the Society of Thoracic Surgeons score (AUC: 0.88; 95% CI: 0.78–0.99 vs. 0.75; 95% CI: 0.64–0.86, respectively; P = 0.036). Finally, when analysing LV remodelling outcomes, ROC curve analysis revealed that low numbers of Tregs (P = 0.017; AUC: 0.69) and increased Th17/Treg ratio (P = 0.012; AUC: 0.70) were predictive of adverse remodelling after TAVI. Conclusions: Our findings demonstrate an association of specific pre-existing inflammatory phenotypes with increased mortality and adverse LV remodelling after TAVI. Distinct monocyte and T-cell signatures might provide additive biomarkers to improve pre-procedural risk stratification in patients referred to TAVI for severe aortic stenosis.
Cerumen was found to be a promising alternative specimen for the detection of drugs. In a pilot study, drugs of abuse were identified at a higher detection rate and a longer detection window in cerumen than in urine. In this study, cerumen from subjects was analyzed after they ingested the designer stimulant 4-fluoroamphetamine (4-FA) in a controlled manner. Methods: Twelve subjects ingested placebo and 100 mg of 4-FA. Five of them were also given 150 mg of 4-FA in 150 mL Royal Club bitter lemon drink at least after 7 days. Cerumen was sampled using cotton swabs at baseline, 1 h after the ingestion of the drug and at the end of the study day (12 h). After extraction with ethyl acetate followed by solid-phase extraction, the extracts were analyzed using liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS). Results and discussion: In the cerumen of all 12 subjects, 4-FA was detected 12 h after its ingestion; in most subjects, cerumen was detected after 1 h of ingestion, ranging from 0.06 to 13.90 (median 1.52) ng per swab. The detection of 4-FA in cerumen sampled 7 days or more after the first dose suggested a long detection window of cerumen. Conclusions: Cerumen can be successfully used to detect a single drug ingestion even immediately after the ingestion when a sufficient amount of cerumen is used.
Background: Approximately one in three patients suffers from preoperative anaemia. Even though haemoglobin is measured before surgery, anaemia management is not implemented in every hospital. Objective: Here, we demonstrate the implementation of an anaemia walk-in clinic at an Orthopedic University Hospital. To improve the diagnosis of iron deficiency (ID), we examined whether reticulocyte haemoglobin (Ret-He) could be a useful additional parameter. Material and Methods: In August 2019, an anaemia walk-in clinic was established. Between September and December 2019, major orthopaedic surgical patients were screened for preoperative anaemia. The primary endpoint was the incidence of preoperative anaemia. Secondary endpoints included Ret-He level, red blood cell (RBC) transfusion rate, in-hospital length of stay and anaemia at hospital discharge. Results: A total of 104 patients were screened for anaemia. Preoperative anaemia rate was 20.6%. Intravenous iron was supplemented in 23 patients. Transfusion of RBC units per patient (1.7 ± 1.2 vs. 0.2 ± 0.9; p = 0.004) and hospital length of stay (13.1 ± 4.8 days vs. 10.6 ± 5.1 days; p = 0.068) was increased in anaemic patients compared to non-anaemic patients. Ret-He values were significantly lower in patients with ID anaemia (33.3 pg [28.6–40.2 pg]) compared to patients with ID (35.3 pg [28.9–38.6 pg]; p = 0.015) or patients without anaemia (35.4 pg [30.2–39.4 pg]; p = 0.001). Conclusion: Preoperative anaemia is common in orthopaedic patients. Our results proved the feasibility of an anaemia walk-in clinic to manage preoperative anaemia. Furthermore, our analysis supports the use of Ret-He as an additional parameter for the diagnosis of ID in surgical patients.
USP22 controls necroptosis by regulating receptor-interacting protein kinase 3 ubiquitination
(2020)
Dynamic control of ubiquitination by deubiquitinating enzymes is essential for almost all biological processes. Ubiquitin-specific peptidase 22 (USP22) is part of the SAGA complex and catalyzes the removal of mono-ubiquitination from histones H2A and H2B, thereby regulating gene transcription. However, novel roles for USP22 have emerged recently, such as tumor development and cell death. Apart from apoptosis, the relevance of USP22 in other programmed cell death pathways still remains unclear. Here, we describe a novel role for USP22 in controlling necroptotic cell death in human tumor cell lines. Loss of USP22 expression significantly delays TNFα/Smac mimetic/zVAD.fmk (TBZ)-induced necroptosis, without affecting TNFα-mediated NF-κB activation or extrinsic apoptosis. Ubiquitin remnant profiling identified receptor-interacting protein kinase 3 (RIPK3) lysines 42, 351, and 518 as novel, USP22-regulated ubiquitination sites during necroptosis. Importantly, mutation of RIPK3 K518 reduced necroptosis-associated RIPK3 ubiquitination and amplified necrosome formation and necroptotic cell death. In conclusion, we identify a novel role of USP22 in necroptosis and further elucidate the relevance of RIPK3 ubiquitination as crucial regulator of necroptotic cell death.
Background and purpose: Superficial siderosis of the central nervous system is a sporadic finding in magnetic resonance imaging, resulting from recurrent bleedings into the subarachnoid space. This study aimed to determine the frequency of spinal dural cerebrospinal fluid (CSF) leaks amongst patients with a symmetric infratentorial siderosis pattern. Methods: In all, 97,733 magnetic resonance images performed between 2007 and 2018 in our neurocenter were screened by a keyword search for “hemosiderosis” and “superficial siderosis.” Siderosis patterns on brain imaging were classified according to a previously published algorithm. Potential causative intracranial bleeding events were also assessed. Patients with a symmetric infratentorial siderosis pattern but without causative intracranial bleeding events in history were prospectively evaluated for spinal pathologies. Results: Forty-two patients with isolated supratentorial siderosis, 30 with symmetric infratentorial siderosis and 21 with limited (non-symmetric) infratentorial siderosis were identified. Amyloid angiopathy and subarachnoid hemorrhage were causes for isolated supratentorial siderosis. In all four patients with a symmetric infratentorial siderosis pattern but without a causative intracranial bleeding event in history, spinal dural abnormalities were detected. Dural leaks were searched for in patients with symmetric infratentorial siderosis and a history of intracranial bleeding event without known bleeding etiology, considering that spinal dural CSF leaks themselves may also cause intracranial hemorrhage, for example by inducing venous thrombosis due to low CSF pressure. Thereby, one additional spinal dural leak was detected. Conclusions: Persisting spinal dural CSF leaks can frequently be identified in patients with a symmetric infratentorial siderosis pattern. Diagnostic workup in these cases should include magnetic resonance imaging of the whole spine.
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma
(2020)
Aims: Changes in metabolism are known to contribute to tumour phenotypes. If and how metabolic alterations in brain tumours contribute to patient outcome is still poorly understood. Epigenetics impact metabolism and mitochondrial function. The aim of this study is a characterisation of metabolic features in molecular subgroups of isocitrate dehydrogenase mutant (IDHmut) and isocitrate dehydrogenase wildtype (IDHwt) gliomas. Methods: We employed DNA methylation pattern analyses with a special focus on metabolic genes, large-scale metabolism panel immunohistochemistry (IHC), qPCR-based determination of mitochondrial DNA copy number and immune cell content using IHC and deconvolution of DNA methylation data. We analysed molecularly characterised gliomas (n = 57) for in depth DNA methylation, a cohort of primary and recurrent gliomas (n = 22) for mitochondrial copy number and validated these results in a large glioma cohort (n = 293). Finally, we investigated the potential of metabolic markers in Bevacizumab (Bev)-treated gliomas (n = 29). Results: DNA methylation patterns of metabolic genes successfully distinguished the molecular subtypes of IDHmut and IDHwt gliomas. Promoter methylation of lactate dehydrogenase A negatively correlated with protein expression and was associated with IDHmut gliomas. Mitochondrial DNA copy number was increased in IDHmut tumours and did not change in recurrent tumours. Hierarchical clustering based on metabolism panel IHC revealed distinct subclasses of IDHmut and IDHwt gliomas with an impact on patient outcome. Further quantification of these markers allowed for the prediction of survival under anti-angiogenic therapy. Conclusion: A mitochondrial signature was associated with increased survival in all analyses, which could indicate tumour subgroups with specific metabolic vulnerabilities.
Purpose: Auditory functional MRI (fMRI) often uses silent inter-volume delays for stimulus presentation. However, maintaining the steady-state of the magnetization usually requires constant delays. Here, a novel acquisition scheme dubbed “pre-Saturated EPI using Multiple delays in Steady-state” (SEPIMS) is proposed, using spin saturation at a fixed delay before each volume to maintain steady-state conditions, independent of previous spin history. This concept allows for variable inter-volume delays and thus for flexible stimulus design in auditory fMRI. The purpose was to compare the signal stability of SEPIMS and conventional sparse EPI (CS-EPI). Methods: The saturation module comprises two non-selective adiabatic saturation pulses. The efficiency of the saturation and its effect on the SEPIMS signal stability is tested in vitro and in vivo. Results: Data show that SEPIMS yields the same signal stability as CS-EPI, even for extreme variations between inter-volume delay durations. However, dual saturation pulses are required to achieve sufficiently high saturation efficiency in compartments with long T1 values. Importantly, spoiler gradient pulses after the EPI readout have to be optimized to avoid eddy-current-induced image distortions. Conclusion: The proposed SEPIMS sequence maintains high signal stability in the presence of variable inter-volume durations, thus allowing for flexible stimulus design.
Background and Objective: Long-term tooth retention is the ultimate goal of periodontal therapy. Aim of this study was to evaluate tooth loss (TL) during 10 years of supportive periodontal therapy (SPT) in periodontal compromised patients and to identify factors influencing TL on patient level. Material and Methods: Patients were re-examined 120 ± 12 months after active periodontal therapy. TL and risk factors [smoking, initial diagnosis, SPT adherence, interleukin-1 polymorphism, cardiovascular diseases, age at baseline, bleeding on probing (BOP), change of practitioner, insurance status, number of SPT, marital and educational status] influencing TL on patient level were assessed. Results: One-hundred patients (52 female, mean age 65.6 ± 11 years) lost 121 of 2428 teeth (1.21 teeth/patient; 0.12 teeth/patient/y) during 10 years of SPT. Forty-two of these were lost for periodontal reasons (0.42 teeth/patient; 0.04 teeth/patient/y). Significantly more teeth were lost due to other reasons (P < .001). Smoking, baseline severity of periodontitis, non-adherent SPT, positive interleukin-1 polymorphism, marital and educational status, private insurance, older age at baseline and BOP, small number of SPT were identified as patient-related risk factors for TL (P < .05). Conclusion: During 120 ± 12 months of SPT, only a small number of teeth was lost in periodontally compromised patients showing the positive effect of a well-established periodontal treatment concept. The remaining risk for TL should be considered using risk-adopted SPT allocation.
CD4+ T cell lymphopenia predicts mortality from Pneumocystis pneumonia in kidney transplant patients
(2020)
Background: Pneumocystis jirovecii pneumonia (PcP) remains a life-threatening opportunistic infection after solid organ transplantation, even in the era of Pneumocystis prophylaxis. The association between risk of developing PcP and low CD4+ T cell counts has been well established. However, it is unknown whether lymphopenia in the context of post-renal transplant PcP increases the risk of mortality. Methods: We carried out a retrospective analysis of a cohort of kidney transplant patients with PcP (n = 49) to determine the risk factors for mortality associated with PcP. We correlated clinical and demographic data with the outcome of the disease. For CD4+ T cell counts, we used the Wilcoxon rank sum test for in-hospital mortality and a Cox proportional-hazards regression model for 60-day mortality. Results: In univariate analyses, high CRP, high neutrophils, CD4+ T cell lymphopenia, mechanical ventilation, and high acute kidney injury network stage were associated with in-hospital mortality following presentation with PcP. In a receiver-operator characteristic (ROC) analysis, an optimum cutoff of ≤200 CD4+ T cells/µL predicted in-hospital mortality, CD4+ T cell lymphopenia remained a risk factor in a Cox regression model. Conclusions: Low CD4+ T cell count in kidney transplant recipients is a biomarker for disease severity and a risk factor for in-hospital mortality following presentation with PcP.
Background: Cerebral O2 saturation (ScO2) reflects cerebral perfusion and can be measured noninvasively by near-infrared spectroscopy (NIRS). Objectives: In this pilot study, we describe the dynamics of ScO2 during TAVI in nonventilated patients and its impact on procedural outcome. Methods and Results: We measured ScO2 of both frontal lobes continuously by NIRS in 50 consecutive analgo-sedated patients undergoing transfemoral TAVI (female 58%, mean age 80.8 years). Compared to baseline ScO2 dropped significantly during RVP (59.3% vs. 53.9%, p < .01). Five minutes after RVP ScO2 values normalized (post RVP 62.6% vs. 53.9% during RVP, p < .01; pre 61.6% vs. post RVP 62.6%, p = .53). Patients with an intraprocedural pathological ScO2 decline of >20% (n = 13) had higher EuroSCORE II (3.42% vs. 5.7%, p = .020) and experienced more often delirium (24% vs. 62%, p = .015) and stroke (0% vs. 23%, p < .01) after TAVI. Multivariable logistic regression revealed higher age and large ScO2 drops as independent risk factors for delirium. Conclusions: During RVP ScO2 significantly declined compared to baseline. A ScO2 decline of >20% is associated with a higher incidence of delirium and stroke and a valid cut-off value to screen for these complications. NIRS measurement during TAVI procedure may be an easy to implement diagnostic tool to detect patients at high risks for cerebrovascular complications and delirium.
Cortical changes in epilepsy patients with focal cortical dysplasia: new insights with T2 mapping
(2020)
Background: In epilepsy patients with focal cortical dysplasia (FCD) as the epileptogenic focus, global cortical signal changes are generally not visible on conventional MRI. However, epileptic seizures or antiepileptic medication might affect normal-appearing cerebral cortex and lead to subtle damage. Purpose: To investigate cortical properties outside FCD regions with T2-relaxometry. Study Type: Prospective study. Subjects: Sixteen patients with epilepsy and FCD and 16 age-/sex-matched healthy controls. Field Strength/Sequence: 3T, fast spin-echo T2-mapping, fluid-attenuated inversion recovery (FLAIR), and synthetic T1-weighted magnetization-prepared rapid acquisition of gradient-echoes (MP-RAGE) datasets derived from T1-maps. Assessment: Reconstruction of the white matter and cortical surfaces based on MP-RAGE structural images was performed to extract cortical T2 values, excluding lesion areas. Three independent raters confirmed that morphological cortical/juxtacortical changes in the conventional FLAIR datasets outside the FCD areas were definitely absent for all patients. Averaged global cortical T2 values were compared between groups. Furthermore, group comparisons of regional cortical T2 values were performed using a surface-based approach. Tests for correlations with clinical parameters were carried out. Statistical Tests: General linear model analysis, permutation simulations, paired and unpaired t-tests, and Pearson correlations. Results: Cortical T2 values were increased outside FCD regions in patients (83.4 ± 2.1 msec, control group 81.4 ± 2.1 msec, P = 0.01). T2 increases were widespread, affecting mainly frontal, but also parietal and temporal regions of both hemispheres. Significant correlations were not observed (P ≥ 0.55) between cortical T2 values in the patient group and the number of seizures in the last 3 months or the number of anticonvulsive drugs in the medical history. Data Conclusion: Widespread increases in cortical T2 in FCD-associated epilepsy patients were found, suggesting that structural epilepsy in patients with FCD is not only a symptom of a focal cerebral lesion, but also leads to global cortical damage not visible on conventional MRI. Evidence Level: 21. Technical efficacy Stage: 3 J. MAGN. RESON. IMAGING 2020;52:1783–1789.
Background and Objectives: Patient blood (more accurately: haemoglobin, Hb) management (PBM) aims to optimize endogenous Hb production and to minimize iatrogenic Hb loss while maintaining patient safety and optimal effectiveness of medical interventions. PBM was adopted as policy for patients by the World Health Organization (WHO), and, all the more, should be applied to healthy donors. Materials and Methods: Observational data from 489 bone marrow (BM) donors were retrospectively analysed, and principles of patient blood management were applied to healthy volunteer BM donations. Results and Conclusion: We managed to render BM aspiration safe for donors, notably completely avoiding the collection of autologous blood units and blood transfusions through iron management, establishment and curation of high-yield aspiration technique, limitation of collection volume to 1·5% of donor body weight and development of volume prediction algorithms for the requested cell dose.
Sphingosine 1-phosphate (S1P) signaling influences numerous cell biological mechanisms such as differentiation, proliferation, survival, migration, and angiogenesis. Intriguingly, our current knowledge is based solely on the role of S1P with an 18-carbon long-chain base length, S1P d18:1. Depending on the composition of the first and rate-limiting enzyme of the sphingolipid de novo metabolism, the serine palmitoyltransferase, other chain lengths have been described in vivo. While cells are also able to produce S1P d20:1, its abundance and function remains elusive so far. Our experiments are highlighting the role of S1P d20:1 in the mouse central nervous system (CNS) and human glioblastoma. We show here that S1P d20:1 and its precursors are detectable in both healthy mouse CNS-tissue and human glioblastoma. On the functional level, we focused our work on one particular, well-characterized pathway, the induction of cyclooxygenase (COX)-2 expression via the S1P receptor 2 (S1P2). Intriguingly, S1P d20:1 only fairly induces COX-2 expression and can block the S1P d18:1-induced COX-2 expression mediated via S1P2 activation in the human glioblastoma cell line LN229. This data indicates that S1P d20:1 might act as an endogenous modulator of S1P signaling via a partial agonism at the S1P2 receptor. While our findings might stimulate further research on the relevance of long-chain base lengths in sphingolipid signaling, the metabolism of S1P d20:1 has to be considered as an integral part of S1P signaling pathways in vivo.
The mammalian target of rapamycin and the integrated stress response are central cellular hubs regulating translation upon stress. The precise proteins and pathway specificity of translation targets of these pathways remained largely unclear. We recently described a new method for quantitative translation proteomics and found that both pathways control translation of the same sets of proteins.
Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In BLAST study (NCT01207388), adults with BCP-ALL in remission with MRD after chemotherapy received blinatumomab, a CD19 BiTE® immuno-oncotherapy, 15 µg/m2/day for up to four 6-week cycles (4 weeks continuous infusion, 2 weeks off). Survival was evaluated for 110 patients, including 74 who received HSCT in continuous complete remission. With a median follow-up of 59·8 months, median survival (months) was 36·5 (95% CI: 22.0–not reached [NR]). Median survival was NR (29.5–NR) for complete MRD responders (n = 84) and 14.4 (3.8–32.3) for MRD non-responders (n = 23; p = 0.002); after blinatumomab and HSCT, median survival was NR (25.7–NR) (n = 61) and 16.5 (1.1–NR) (n = 10; p = 0.065), respectively. This final analysis suggests complete MRD response during blinatumomab treatment is curative. Post-hoc analysis of study data suggests while post blinatumomab HSCT may be beneficial in appropriate patients, long-term survival without HSCT is also possible.
Introduction: Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from non-small cell lung cancer. Methods: Tyrosine kinase inhibitor adherence was measured electronically by MEMS® (medication event monitoring system) over at least six months. Adherence rates were calculated in terms of Dosing Compliance, Timing Compliance, Taking Compliance, and Drug Holidays. Patients were dichotomized as adherent when Dosing Compliance and Timing Compliance were ≥80%, Taking Compliance ranged between 90 and 110%, and <1 Drug Holiday was registered. Quality of life was assessed by two questionnaires (EORTC QLQ-C30 version 3.0, EORTC QLQ-LC13) at three time points. Adverse drug events were reported via patient diaries. Results: Out of 32 patients enrolled, data from 23 patients were evaluable. Median Dosing Compliance, Taking Compliance, and Timing Compliance adherence rates of tyrosine kinase inhibitor intake amounted to 100%, 98%, and 99%, respectively; Drug Holidays were observed in three patients. Four patients were dichotomized as non-adherent. Three of them had a twice-daily tyrosine kinase inhibitor regimen. Median quality of life scores amounted to 67 (max. 100) and remained unchanged over the study period. Fatigue and rash were the most frequently reported adverse drug events. Conclusion: Medication adherence of non-small cell lung cancer patients treated with tyrosine kinase inhibitors was extraordinarily high and is likely to support the effectiveness of tyrosine kinase inhibitor treatment and a good quality of life over a long period of time. Adherence facilitating information and education is especially relevant for patients taking tyrosine kinase inhibitors in a twice-daily regimen.
Aim: The aim of this study is to utilize the niche measurement guidelines outlined by Jordans et al. in order to establish normal values and accurate description of caesarean section scars in a normal population. After defining the normal distribution, abnormal pregestational scar characteristics will be identified for predicting adverse pregnancy outcomes. Methods: This is a prospective observational multicenter clinical study where women with a history of only one caesarean section and yet open family planning are enrolled. The uterine length, cervical length, niche length, niche depth, niche width, residual myometrial thickness, endometrial thickness, scar to internal os distance, anterior myometrial thickness superior and inferior to the scar and the posterior myometrial thickness opposite the scar, superior and inferior to it are measured in a pregestational uterus. The lower uterine segment is measured over a length of 3 cm during subsequent pregnancy and followed up until delivery. Results: Data from 500 patients will yield normal distribution curves for all predefined measurements. Establishing a correlation between deviations from the normal measures and adverse events would be instrumental for counseling women regarding subsequent pregnancy and mode of delivery.
Conclusion: This study will demonstrate the changes of the post-caesarean scar from a non-pregnant uterus until delivery and can confirm the importance of the scar characteristics in predicting pregnancy outcome.
Background: Brodalumab is a fully human monoclonal immunoglobulin IgG2 antibody that binds to the human IL-17 receptor subunit A and by that inhibits the biologic action of IL-17A, IL-17F, IL-17C and IL-17E. Therapy with fumaric acid esters (FAE) is a well established and widely used first-line systemic treatment for subjects with moderate-to-severe plaque psoriasis. Objectives: To compare brodalumab to FAE in terms of clinical efficacy, patient-reported outcomes and safety in subjects with moderate-to-severe plaque psoriasis who were naïve to systemic treatment. Methods: Eligible subjects were randomized 1 : 1 to 210 mg brodalumab injections or oral FAE according to product label in this 24-week, open-label, assessor-blinded, multi-centre, head-to-head phase 4 trial. The primary endpoints were having PASI75 and having sPGA score of 0 or 1 (sPGA 0/1). Subjects with missing values for the primary endpoints were considered non-responders. Results: A total of 210 subjects were randomized. 91/105 subjects completed brodalumab treatment and 58/105 subjects completed FAE treatment. At Week 24, significantly more subjects in the brodalumab group compared to the FAE group had PASI75 (81.0% vs. 38.1%, P < 0.001) and sPGA 0/1 (64.8% vs. 20.0%, P < 0.001). In the brodalumab group, the median time to both PASI75 and to PASI90 was significantly shorter than in the FAE group (4.1 weeks vs. 16.4 weeks, and 7.4 weeks vs. 24.4 weeks, respectively, P < 0.0001 for both). The rate of adverse events was lower in subjects treated with brodalumab compared to subjects treated with FAE (616.4 vs. 1195.8 events per 100 exposure years). No new safety signals were detected for brodalumab. Conclusions: Brodalumab was associated with rapid and significant improvements in signs and symptoms of moderate-to-severe plaque psoriasis, with a superior efficacy profile to what was observed with FAE in systemic-naïve subjects over 24 weeks.